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The aim of this study was to estimate the cost-effectiveness of negative-pressure wound 
therapy (NPWT) in comparison to standard wound management after initial surgical wound 
debridement in adults with severe open fractures of the lower limb. 
Patients and Methods 
An economic evaluation was conducted from the perspective of the United Kingdom 
National Health Service and Personal Social Services, based on evidence from the 460 
participants in the Wound management of Open Lower Limb Fractures (WOLLF) trial.  
Economic outcomes were collected prospectively over the 12-month follow-up period using 
trial case report forms and participant-completed questionnaires. Bivariate regression of 
costs (£, 2014-15 prices) and quality-adjusted life years (QALYs), with multiple imputation of 
missing data, was conducted to estimate the incremental cost per QALY gained associated 
with NPWT dressings. Sensitivity analyses and sub-group analyses were undertaken to 
assess the impacts of uncertainty and heterogeneity, respectively, surrounding aspects of 
the economic evaluation. 
Results 
The base case analysis produced an incremental cost-effectiveness ratio of £267,910 per 
QALY gained, reflecting on average higher costs (£678; 95% confidence interval (CI): -
£1082, £2438) and only marginally higher QALYS (0.002; 95% CI: -0.054, 0.059) in the 
NPWT group. The probability that NPWT is cost-effective in this patient population did 
not exceed 27% regardless of the value of the cost-effectiveness threshold. This result 




This trial-based economic evaluation suggests that NPWT is unlikely to be a cost-effective 
strategy for improving outcomes in adult patients with severe open fractures of the lower 





High-energy fractures of the lower limb are common in civilian and military populations,1,2 
with long-term consequences for the individuals affected and for the health services if 
inadequately managed.3,4 In cases of ‘open’ fracture, exposure to contamination from the 
environment increases the risk of complications.5 Infection rates may be as high as 27%, 
even in specialist trauma centres.6  
     Studies of the economic costs associated with the management of open lower limb 
factures are lacking. Limited evidence suggests that wound complications in patients with an 
open fracture of the lower limb, such as deep surgical site infection (SSI), lead to increased 
economic costs and significantly impaired health-related quality of life over the first 12 
months following injury.7. One economic study conducted in eight US trauma centres 
estimated a mean two-year health care cost of $91,106 for patients treated with 
amputation (2002 prices).8  
     Current guidelines recommend that open lower limb factures are initially managed with 
antibiotics and surgical excision (debridement) to remove damaged tissue and 
contamination.9 For those fractures that cannot be closed primarily after this first wound 
excision, the traditional approach in the UK National Health Service (NHS) and military 
practice has been to protect the wound from further contamination with the application of 
a temporary, sealed, non-adhesive layer, followed by further wound excision and definitive 
closure or soft-tissue reconstruction within 72 hours. Negative-pressure wound therapy 
(NPWT) has been recommended as the optimal form of wound dressing that can be applied 
to open fractures between the first wound excision and definitive closure.9 NPWT creates a 
partial vacuum over the wound using suction to remove blood, exudate any residual 
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bacteria from the area, and may also encourage the formation of granulation (healing) 
tissue.10  
     The decision surrounding whether to adopt NPWT as a treatment for open lower limb 
fractures should be informed by evidence on its clinical and cost-effectiveness. Published 
evidence on the cost-effectiveness of NPWT has been limited to other clinical indications, 
including high-risk caesarean section wounds,11 infected vascular groin graft wounds,12 and 
primary hip and knee replacements.13 In this paper, we present the first economic 
evaluation of NPWT among adults with severe open fractures of the lower limb, based on 






The WOLLF trial (ISRCTN33756652) was a pragmatic, randomised controlled trial conducted 
in 24 specialist trauma hospitals in the UK Major Trauma Network during July 2012 through 
April 2017. Eligible patients, aged ≥16 years and presenting with a severe, open fracture of 
the lower limb, were randomly assigned on a 1:1 basis to NPWT or a standard wound 
dressing after the first surgical debridement of the open fracture wound. The trial required a 
sample size of 460 to detect a difference of eight points in the primary clinical outcome, the 
Disability Rating Index score (DRI; score 0 [no disability] to 100 [completely disabled]) at 12 
months.14 The sample size was calculated using a two sample t-test and assumed a standard 
deviation of 25, 90% power and a 5% significance level, and allowed for a margin of 10% loss 
during follow-up.15 The study had the approval of the Coventry Research Ethics Committee 
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(REC reference 10/57/20) and the Research and Development department of each 
participating centre. Further details of the WOLLF trial, its sampling procedures, 
methodology, clinical outcome measures and response rates are reported elsewhere.15 
 
Type of economic evaluation, study perspective and time horizon 
 
The economic evaluation took the form of a cost-utility analysis, expressed in terms of 
incremental cost attributable to the NPWT dressing per quality-adjusted life year (QALY) 
gained. The QALY, a preference-based outcome measure that captures changes in both 
length and health-related quality of life, is recommended by agencies such as the National 
Institute for Health and Care Excellence (NICE) in England, for cost-effectiveness based 
decision making.16 The primary analysis adopted a National Health Service (NHS) and 
Personal Social Services (PSS) perspective in accordance with NICE methodological 
guidance.16 Cost-effectiveness was determined over a 12 month time horizon, which 
mirrored the follow-up period of the WOLLF trial. Consequently, no discounting of cost or 
QALY values was required. 
  
Costings of NPWT and standard dressings 
 
Staff and consumable resource inputs for both types of wound dressings, and number of 
dressing changes, were estimated using prospectively recorded data for a sample of 38 
WOLLF participants (n=20 randomised to NPWT; n=18 randomised to standard wound 
dressing). The NPWT dressing comprised of the dressing pack (an average cost for the 
available sizes was used), the canister and the pump (a daily rental cost was applied to the 
8 
 
period of initial hospitalisation relevant to the open fracture wound). The type of standard 
wound dressing was left to the discretion of each surgical team. NHS costs for staff and 
consumable resource inputs associated with wound dressings were obtained from the 
finance department within the sponsor site, University Hospitals Coventry and Warwickshire 
NHS Trust.  
 
Costing of initial hospitalisation and readmissions 
 
For many participants within the WOLLF trial, their inpatient resource use was complex and 
featured multiple procedures and postoperative complications as well as multiple 
readmissions. In order to estimate the cost of each initial hospital admission, we extracted 
information from the battery of trial case report forms on all procedures carried out, 
including those associated with postoperative complications and further surgical 
interventions. Using the HRG4+ 2015/16 reference cost guidance, participant-level profiles 
of procedures were assigned to healthcare resource groups (HRGs) for each initial 
admission, which were then related to costs using the NHS reference cost 2014/15 
schedule.17 Where insufficient information was available to reliably assess the procedure(s) 
carried out during the initial inpatient admission, further operation notes and/or discharge 
letters were requested from trial sites for clarification.  
     In order to assign costs to readmissions, it was first necessary to determine which 
readmissions were related to the open fracture, which was based on clinical judgement 
using complication data reported by independent research staff at six weeks post-
randomisation, data provided by participants within questionnaires completed at three, six, 
nine and 12 months post-randomisation, and data extracted from trial serious adverse 
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event forms completed by the local trial staff. Operation notes were then requested from 
sites for all relevant readmissions, allowing the procedures carried out during each 
readmission to be determined. HRG codes could then be determined for each readmission 
and related to NHS reference costs. For cases where there was evidence of a related 
readmission, but the specific procedure carried out was unknown, a weighted average of 
the base costs, average length of stay and excess bed day cost for the five most common 
procedures carried out during readmissions was assumed.  
 
Measurement of broader resource use 
 
As well as hospital inpatient resource use related to the initial admission and readmissions, 
data were also collected on broader NHS and PSS resource use as well as societal resource 
use for the period between randomisation and 12 months post-randomisation. Trial 
participants self-completed resource use questionnaires at three, six, nine and 12 months 
post-randomisation, reporting their use of hospital outpatient and day care services, 
community health care, medications, personal social services and aids and adaptations that 
could be attributed to the open fracture. The three month questionnaire covered the period 
from initial hospital discharge to three months post-randomisation, with subsequent 
questionnaires retrospectively covering each three month period. Further questions 
captured wider societal attributable resource use, with data collected on time off work, over 
the counter medications, aids and adaptations purchased privately as well as any additional 





Valuation of broader resource use  
 
Resource inputs were valued using a combination of primary research, based on established 
accounting methods, and data from secondary national tariff sets. Costs were applied to 
inpatient hospital care resource use as described above. For outpatient hospital care, costs 
per contact from the 2014/15 NHS Reference Costs schedules were multiplied by numbers 
and types of contacts in each hospital department.17 For community health and social 
services, unit costs were primarily extracted from the PSSRU Unit Costs of Health and Social 
Care compendium.18 Where trial participants provided data on the mean duration of each 
community health or social care contact, the unit cost per minute was applied to these 
inputs. Where unavailable, the mean cost per contact was used. Medication costs were 
derived from NHS Prescription Cost Analysis database.19 Where data on dose, the number of 
uses daily and the number of days of use was available, this granulated information was 
used to inform medication costs. Where this was unavailable, a combination of clinical input 
and the mean values of other trial participants using the same medication was used. Aids 
and adaptations were valued using a combination of data from NHS Supply Chain Catalogue 
as well as other sources.20 For aids and adaptations that could reasonably be assumed to be 
returned to the NHS following use, items were assumed to last for five years with no resale 
value and a discount rate of 3.5% was used to calculate an annuitised cost, which was then 
applied to the period of use during the trial.21 Time off work was valued using income data 
from the Office for National Statistics 2014 New Earnings Survey, categorised by age and 
gender.22 Unit costs were inflated/deflated to 2014-15 prices where necessary using the 
NHS Hospital and Community Health Services Pay and Prices Index for health service 
resource inputs, and the Consumer Prices Index for broader resource inputs.18  
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Calculation of utilities and QALYs 
 
The health-related quality of life of WOLLF participants was measured using the EuroQol EQ-
5D-3L collected at baseline (including an assessment of  immediate post-injury health-
related quality of life, as well as separate retrospectively recalled pre-injury values) and at 
three, six, nine and 12 months post-randomisation.23  The EQ-5D-3L consists of both a 
descriptive system and a visual analogue scale ranging from 100 (best imaginable health 
state) to 0 (worst imaginable health state). The descriptive system defines health-related 
quality of life across five dimensions: mobility, self-care, usual activities, pain and anxiety or 
depression. Responses in each dimension take the form of “no problems”, “some or 
moderate problems” or “severe or extreme problems”. Responses to each of these five 
dimensions can then be valued on a health utility scale from -0.59 to 1, with negative values 
relating to health states considered worse than death, zero equivalent to being dead, and 1 
being a state of full health. For the purposes of this study, the York A1 tariff set was applied 
to each set of responses to generate an EQ-5D utility score for each participant.24  QALYs 
were calculated as the area under the baseline-adjusted25 utility curve of EQ-5D-3L utility 
scores across the (immediate post-injury) baseline, three, six, nine and 12 month time 
points, using the trapezoidal rule.21   
     Within the WOLLF trial, the SF-12 v2 was also collected at baseline, as well as at three, 
six, nine and 12 months post-randomisation. The SF-12 v2 is a generic health measure with 
12 questions covering aspects of physical and mental health across eight dimensions. The 
UK standard gamble tariff was applied to the responses to the SF-12 in order to generate SF-
6D utility scores, from which QALYs could be re-calculated using the trapezoidal rule for the 





Missing data were anticipated to be a problem. For all analyses except the complete case 
analysis, multiple imputation was therefore used. Multiple imputation produces unbiased 
estimates of a treatment effect provided data are missing at random (i.e. missingness is not 
related to the value itself, but is related to the values of observed variables) or missing 
completely at random (i.e. missing data has no relation to the value of any other factors in 
the study population). Missing at random mechanisms within our data were explored using 
logistic regression analysis with missingness (of costs and QALYs) as the (binary) response 
variable and baseline covariates as explanatory variables. Multiple imputation using chained 
equations with predictive mean matching was carried out on total QALYs over the entire 
one year follow-up period, total costs in each follow-up period (baseline to three months, 
three to six months, six to nine months and nine to 12 months) and on pre-injury and post-
injury baseline EQ-5D utility scores.27 Also included within the imputation models were 
predictive covariates. These included: costs associated with initial hospitalisations and 
dressing changes, trial site, Gustilo-Anderson wound grade,28 gender and age. A total of 69 
imputed datasets were generated for the base case analysis, following the “rule of thumb” 
suggested in recent methodological guidance, which were subsequently combined using 
Rubin’s rule.27  
 




A mixed-effects regression analysis, with recruiting centre as a random effect, and fixed 
terms to adjust for age group, sex, baseline preinjury score and Gustilo-Anderson wound 
grade was used to test for treatment group differences for the primary clinical outcome.15 
Resource use items were summarised by trial allocation group and follow-up period and 
differences between groups were analysed using two-sample t-tests for continuous 
variables and Pearson chi-squared (χ2) test for categorical variables. Means and standard 
errors (SEs) for values of each cost category were estimated by treatment allocation and 
follow-up period. Statistical differences in mean costs by treatment allocation were 
assessed using two-sample t-tests. Mean total costs by treatment allocation and follow-up 
period were also estimated. Statistically significant differences in the mean total costs were 




Bivariate regression using seemingly unrelated regression was used to model total costs and 
total QALYs over the one year follow-up period. This approach allows for correlation 
between costs and outcomes and estimates the two regression equations jointly, potentially 
improving the precision of the estimates. By specifying the treatment group as an indicator 
within each equation, the incremental costs and QALYs attributable to NPWT were 
estimated, whilst controlling for baseline covariates (age, gender, trial site and Gustilo-
Anderson wound grade). Within the equation for QALYs, baseline EQ-5D utility scores (both 
pre-injury and post-injury) were included to adjust for potential baseline imbalances 
between the trial allocation groups.25 Cost-effectiveness was expressed in terms of an 
incremental cost-effectiveness ratio (ICER), defined as the incremental cost of NPWT divided 
14 
 
by the incremental QALYs produced by NPWT. The ICER was then compared to cost-
effectiveness threshold values for an additional QALY. The NICE cost-effectiveness threshold 
for UK-based studies ranges between £20,000 and £30,000 per QALY.16 In addition, a 
£15,000 cost-effectiveness threshold was considered to reflect more recent trends in 
healthcare decision making.29  
     By bootstrapping30 the data with replacement and recalculating these incremental costs 
and QALYs 1000 times, a cost-effectiveness plane was populated with 1000 simulated ICER 
values.31 The cost-effectiveness plane provides a graphical representation of ICER values 
with the difference in QALYs between NPWT and standard wound dressing shown on the X-
axis (ICERs to the east of the origin represent positive QALY effects), while the Y-axis shows 
the difference in cost (ICERs to the north of the origin represent positive cost effects). Net 
monetary benefits were estimated from the incremental costs and QALYs at each given 
cost-effectiveness threshold value and reflect the resource gain or loss due to investing in 
NPWT, given that resources can be used elsewhere within the NHS at the same cost-
effectiveness threshold.32 By calculating net monetary benefits for each of these 1000 
simulated ICER values at levels of the cost-effectiveness threshold varying from £0 to 
£50,000 per QALY gained, the probability of cost-effectiveness of NPWT (defined as the 
proportion of positive net monetary benefits at a given threshold level) was calculated, and 
plotted as a cost-effectiveness acceptability curve.33  
 
Sensitivity and sub-group analyses 
 
Several sensitivity analyses were undertaken to explore the effects of alternative 
perspectives or scenarios on the cost-effectiveness results. The cost-effectiveness analysis 
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was therefore repeated under the following assumptions: 1) adopting a wider societal 
costing perspective, i.e. including costs to individuals and the broader economy; 2) 
calculating QALYs using the SF-6D instead of the EQ-5D-3L; and 3) restricting the analysis to 
complete cases only.  
     A single pre-specified sub-group analysis was also conducted to explore potential 
heterogeneity in the incremental cost-effectiveness of NPWT related to whether or not 
there was evidence of deep infection, assessed using the CDC SSI algorithm.34  
     All statistical analyses were conducted using Stata SE V.14 (Statacorp. Stata Statistical 
Software: Release 14: College Station, TX: Statacorp LP, 2015). Results of statistical tests 





A total of 460 participants were consented into the WOLLF trial, of whom 226 were 
randomised to the NPWT dressing and 234 to a standard wound dressing. There was no 
statistically significant difference in the mean Disability Rating Index score at 12 months 
(45.5 (standard deviation (SD): 28.0) in the NPWT group vs 42.4 (SD: 24.2) in the standard 
dressing group; mean difference −3.9 in favour of standard dressings with 95% confidence 
interval (CI): −8.9 to 1.2; P = 0.132; from adjusted mixed-effect regression analysis). Full 
details of the clinical outcomes of the WOLLF trial are reported elsewhere.15 The 
completeness of the relevant health economic data items, by trial group, follow-up point 
and resource category is provided in Appendix I.  Complete economic profiles, 
encompassing all cost and utility data at all time points, were available for 144 (31%) 
16 
 
participants [65 (29%) participants in the NPWT group and 79 (34%) participants in the 
standard dressing group] with evidence that participants with complete data were 
unrepresentative of the total study population. In particular, complete economic profiles 
were more likely to be available for women and for older age groups. 
 
Resource use and economic costs 
 
Primary procedures, and their associated lengths of hospital stay, are broken down by trial 
arm and detailed in Appendix II. The most common primary procedure was the latissimus 
dorsi free-flap, which was performed in 130 trial participants. There was a statistically 
significant difference in the percentage of participants receiving a sliding hip screw as their 
primary procedure between the two trial arms (0 (0%) in the NPWT group vs 8 (3.4%) in the 
standard dressing group; P = 0.005 from χ2 test). There were no other statistically significant 
differences in the type of fixation nor in length of stay for each primary procedure between 
the two trial arms. 
     The resource components associated with NPWT and standard dressings, as well as 
dressing changes, and their associated economic costs are summarised in Table I. Appendix 
III presents resource use values for trial participants with complete data by trial allocation, 
follow-up period and resource category. Mean hospital readmission rates related to the 
open fracture wound were similar between trial arms (0.22 vs 0.22 between initial hospital 
discharge and 3 months declining to 0.11 vs 0.11 during the 9-12 month follow-up period). 
Within outpatient resource use, the department with the highest mean number of visits per 
participant was NHS physiotherapy, which peaked at 4 visits during the 3-6 month follow-up 
period for participants randomised to standard dressings. During the 6-9 month follow-up 
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period, participants randomised to standard dressings made significantly more NHS 
physiotherapy visits (mean of 3.21 vs 1.64; P = 0.040 from two-sample t-test), an effect 
mirrored for private physiotherapy visits (0.78 vs 0.41), although the latter difference was 
not statistically significant (P = 0.265 from two-sample t-test). Prescription medication usage 
was highest during the first three months post-randomisation (53% of all participants). 
During the 3-6 month follow-up period, this had fallen to 42% of participants, with higher 
medication usage amongst participants randomised to standard dressings (48% vs 36%; P = 
0.044 from χ2 test). Resource use values were combined with unit costs for each resource 
item (Table II) to estimate economic costs for each resource category.  
     Economic costs for trial participants with complete data are presented in Table III by trial 
arm, study period and cost category. With the exception of the cost of the initial inpatient 
stay (including costs associated with dressings and dressing changes), there were no 
statistically significant differences in costs between the trial arms during any study period or 
in any cost category. For the initial patient stay, mean unadjusted costs were £1,223 
(bootstrap 95% CI: £211, £2,364) higher in the NPWT arm (P = 0.030 from two-sample t-
test). Over the entire follow-up period, mean unadjusted NHS and PSS costs, inclusive of the 
additional cost of the intervention and associated dressing changes, were £14,079 in the 
NPWT group, compared to £14,002 in the standard dressing group, generating an 
unadjusted mean cost difference of £77 (bootstrap 95% CI: -£2,114, £2,925; P = 0.953 from 
two-sample t-test). 
 




Table IV summarises the cost-effectiveness results based on the WOLLF trial. The base case 
analysis, using multiple imputed data, covariate adjustment and conducted from a NHS and 
PSS perspective, produced an ICER of £267,910 per QALY gained, reflecting higher costs and 
marginally higher QALYs, on average, in the NPWT arm. The probability that NPWT is cost-
effective didn’t exceed 27% across a range of cost-effectiveness thresholds (24.4% at the 
widely used £20,000 cost-effectiveness threshold), whilst mean net monetary benefits were 
negative across a range of cost-effectiveness thresholds. The cost-effectiveness plane and 
cost-effectiveness acceptability curve that summarise the results of the base case analysis 
are displayed in Figure I. The cost-effectiveness acceptability curve shows that the 
probability that NPWT is cost-effective does not exceed 0.27 regardless of the value of the 
cost-effectiveness threshold. 
 
Sensitivity and subgroup analyses 
 
A range of sensitivity analyses explored the effects of uncertainty surrounding components 
of the economic evaluation (Table IV). Adopting a broader societal perspective that 
additionally included costs that fell outside of the NHS and PSS sectors increased the mean 
ICER to £282,858 per QALY gained, largely driven by an increased incremental cost 
attributable to NPWT, whilst the probability that NPWT is cost-effective did not exceed 11%. 
When QALYs were calculated using the SF-6D utility measure rather than the EQ-5D-3L, 
NPWT was strictly dominated by standard dressings, implying that NPWT resulted in both 
higher costs and worse outcomes, on average. Finally, restricting the analysis to complete 
cases resulted in a qualitative change in the direction of the results with NPWT becoming 
dominant in health economic terms, that is, it generated both lower costs and higher QALYs, 
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on average. In this analysis, the probability that NPWT is cost-effective exceeded 70% across 
a range of cost-effectiveness thresholds. 
     A pre-specified subgroup analysis was also carried out to explore the cost-effectiveness 
of NPWT in those participants with a deep infection (Table IV). NPWT was dominated in this 
group of participants, generating increased costs and lower QALYs, on average, whilst the 





This paper presents the first economic evaluation of NPWT among adults with severe open 
fractures of the lower limb, based on evidence from the WOLLF trial. The study revealed 
very little difference in health-related quality of life outcomes measured during the 12 
months following injury. The cost-effectiveness conclusions are therefore largely driven by 
mean cost difference between the comparator interventions. The base case analysis that 
used multiple imputed data and covariate adjustment generated a mean ICER of £267,910 
per QALY gained, well in excess of accepted cost-effectiveness thresholds.16 Consequently, 
the probability that NPWT is cost-effective did not exceed 27% in the base-case analysis. 
This result remained robust to several sensitivity analyses and the pre-specified sub-group 
analysis. The only exception to this pattern of results followed the complete case analysis, 
which was restricted to 31% of the study population, where NPWT was associated with 
lower costs and higher QALYs, on average. 
     Previous economic evaluations of NPWT were conducted in clinical contexts outside of 
the management of open fractures of the lower limb,11-13 and therefore a comparative 
20 
 
assessment of cost-effectiveness evidence is not possible. Moreover, previous economic 
analyses of lower limb fractures have either taken the form of cost of illness studies,35 which 
cannot inform decisions around allocative efficiency, or have focussed on other elements of 
the care pathway, such as the use of locking and non-locking implants, whilst also excluding 
assessments of health-related quality of life outcomes and cost-effectiveness.36 In the 
absence of directly related evidence from the broader literature, evidence from this study 
provides the sole source of information on the cost-effectiveness of NPWT among adults 
with severe open fractures of the lower limb that clinical decision-makers can draw upon. 
     The economic evaluation reported in this paper was conducted according to nationally 
agreed design and reporting guidelines.16,37 It was based on a pragmatic randomised, multi-
centre, controlled trial that avoids many of the selection biases that characterise 
observational studies and that provided a vehicle for comprehensive prospective 
assessments of resource use and preference-based health-related quality of life outcomes. 
The study’s cost accounting was rigorous and included all significant resource items 
calculated from a NHS and PSS perspective and additionally from a societal perspective. A 
comprehensive analytical strategy was pursued to handle sampling uncertainty surrounding 
the baseline ICERs and decision uncertainty surrounding the value of the cost-effectiveness 
threshold. Moreover, the pre-specified analytical design allowed for the estimation of 
longer term cost-effectiveness beyond the trial time horizon in the event of evidence for 
benefit over the medium term. We believe that the absence of significant differences in 
costs or preference-based health-related quality of life outcomes over the 12-month trial 




     Readers should consider a number of caveats when interpreting the study results. First, 
as expected in the context of emergency surgery in severely injured patients, some patients 
were found to be ineligible for inclusion in the trial following randomisation as a result of, 
for example, permanent cognitive impairment that could not be recognised at an earlier 
stage within the care pathway. Nevertheless, 460 of the 485 (95%) patients who were 
randomised and deemed eligible for the trial agreed to participate, suggesting that the cost-
effectiveness results are generalisable to the broader UK adult population with severe open 
fractures of the lower limb. Second, several categories of resource use, such as community 
health and social care resource use, were measured through repeated participant recall 
over three month periods, which can be prone to recall biases.38 Nevertheless, we had no 
evidence of a differential effect of recall biases between the trial arms, which could have 
required a further adjustment of our cost-effectiveness estimates. Third, complete health 
economic data over the study follow-up period was only available for 31% of trial 
participants (Appendix I) with evidence that participants with complete data differed from 
those with incomplete data across a range of clinical and sociodemographic characteristics. 
Had our base case cost-effectiveness analysis only considered individuals with complete 
economic data, we would have removed 69% of participants from the analysis, which would 
have likely biased the results. We therefore handled missingness within the health 
economic data through recommended multiple imputation techniques that address the 
inherent biases associated with estimating effects on the basis of complete data.39 
Moreover, the base case cost-effectiveness outcomes remained robust following additional 
sensitivity analyses that tested alternative missing data mechanisms and alternative model 
specifications that varied the explanatory variables incorporated. Finally, our approach to 
estimating QALYs, which involved assessing health-related quality of life outcomes at three 
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month intervals, may not have captured the short-term disutility of NPWT immediately 
post-randomisation. Nevertheless, the NPWT device was worn for a mean of only 3 days 
(range 2-5 days) and, consequently, any associated disutility is likely to have minimal impact 
on incremental QALY calculations. 
     In conclusion, this study found that NPWT is unlikely to be a cost-effective strategy for 
improving outcomes in adult patients with severe open fractures of the lower limb. Data 
from our study can be used to inform future economic evaluations and value of information 






Tables showing: (i) completeness of health economic data by trial group, follow-up point 
and resource category (Appendix I); (ii) primary initial procedures by trial arm (Appendix II): 
and (iii) resource use values by trial allocation, follow-up period and resource category in 
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Table I: Staff and consumable costs (£, 2014/15 prices#) associated with dressings and dressing 
changes 
Dressing variable Cost Source 
NPWT dressing elements   
VAC dressing pack 31.67 Personal communication 
VAC canister 34.87 Personal communication 
VAC pump - daily rental cost 17.56 Personal communication 
Standard dressing elements   
Mepitel 8cmx10cm 3.46 NHS supply chain 2015/16 
Dressing gauze 0.21 NHS supply chain 2015/16 
Formflex Natural Sterile 
Padding Bandage 10cm x 2.7m 
0.39 NHS supply chain 2015/16 
Premier Band Light Support 
Bandage 10cm x 4.5cm 
0.60 NHS supply chain 2015/16 
Mean cost per dressing change 
- NPWT 
22.40  
Mean cost per dressing change 
- Standard dressing 
6.12  
Mean additional cost of NPWT  16.28  
Mean number of dressing 
changes - NPWT 
2.05  
Total additional cost of NPWT 
dressing changes 
33.37  
# Where relevant, prices were deflated to 2014/15 prices using the NHS hospital and community 
health services pay and prices index. VAC denotes vacuum-assisted closure. 
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Table II: Unit costs for resource items; (£, 2014/15 prices#) 
Resource category (unit 
used for costing purposes) 
Unit cost  
 
Unit cost  
(per minute) 
Source 
Outpatient care    
Orthopaedics (visit) 112.5  NHS references costs 2014/15 
Pathology (visit) 77.7  NHS references costs 2014/15 
Radiology (visit) 82.37  NHS references costs 2014/15 
Physiotherapy (NHS) (visit) 46  NHS references costs 2014/15 
Physiotherapy (Private) 
(visit) 
45.54  NHS references costs 2014/15 
Emergency Department 
(visit) 
140.59  NHS references costs 2014/15 
Community health care    
GP visits in surgery (visit) 44.46 3.8 PSSRU 2014/15 
GP home visits (visit) 43.32 3.8 PSSRU 2014/15 
GP telephone contacts 
(contact) 
 26.98 3.8 PSSRU 2014/15 
Practice nurse contacts 
(contact) 
14.47 0.93 PSSRU 2014/15 
District nurse contacts 
(contact) 
38 1.12 PSSRU 2014/15 
Community physiotherapy 
contacts (contact) 
34.05 0.61 PSSRU 2013/14 
Calls to NHS direct (call)  20.18  bbc.co.uk 
Calls for an ambulance or 
paramedic (call) 
99  PSSRU 2014/15 
Occupational therapy 
contacts (contact) 
77.69 0.61 PSSRU 2013/14 
Personal social services    
Meals on wheels (meal) 6.55  PSSRU 2009/10 
Laundry services (service) 9.78  housingcare.org 
Social worker contacts 
(contact) 
49.28 1.32 PSSRU 2014/15 
Care worker contacts 
(contact) 
18.5 0.62 PSSRU 2014/15 
Aids and adaptations    
Crutches (item) 5.06  NHS supply chain catalogue 
2015/16 
Stick (item) 3.94  NHS supply chain catalogue 
2015/16 
Zimmer frame (item) 21.54  completecareshop.co.uk 
Grab rail (item) 1.61  NHS supply chain catalogue 
2015/16 
Dressing aids (item) 5.34  NHS supply chain catalogue 
2015/16 
Long-handle shoe horn 
(item) 
1.66  NHS supply chain catalogue 
2015/16 
#Where relevant, prices were inflated/deflated to 2014/15 prices using the NHS hospital and community 





Table III: NHS and Personal Social Service Costs (£, 2014/15 prices) by cost category and follow-up 
point; complete cases 
Cost category NPWT 
Mean Cost  
(95% CI)  
Standard 
Mean Cost 
 (95% CI)  
Mean 
Difference 
Bootstrap 95% CI P 
value± 
 







1223.1 (210.6, 2363.8) 0.030  




-96.6 (-568.6, 434.6) 0.705  




-79.6 (-216.2, 70.7) 0.271  























-3.4 (-10.8, 1.8) 0.277  






980.0 (-162.5, 2255.0) 0.115  
3 months to 6 months (n = 277 complete cases of 460 total) 




-117.9 (-582.3, 464.9) 0.656  




-48.9 (-193.7, 96.5) 0.496  























-0.2 (-7.4, 7.9) 0.965  






181.0 (-464.7, 996.0) 0.622  
6 months to 9 months (n = 262 complete cases of 460 total) 




190.6 (-263.5, 572.7) 0.371  




-96.6 (-225.3, -1.1) 0.086  























0.2 (-1.8, 1.9) 0.751  






114.9 (-403.6, 598.8) 0.652  
9 months to 12 months (n = 322 complete cases of 460 total) 




165.3 (-111.5, 765.9) 0.409  
Outpatient care 261.7 
(197.0, 326.4) 
254.3 
 (189.8, 318.8) 
7.4 (-87.7, 95.7) 0.873  




-16.5 (-61.7, 22.5) 0.444  
Medications 16.4 24.6 -8.2 (-44.6, 9.7) 0.504  
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-0.5 (-14.7, 5.1) 0.918  






150.1 (-176.1, 815.4) 0.508  
Baseline to 12 months (n = 152 complete cases of 460 total) 










76.8 (-2114.3, 2925.4) 0.953  
±  Two-sample t-test;   Calculated using non-parametric bootstrap estimation using 1000 replications, bias corrected.
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Table IV: Cost-effectiveness results for base case analysis and sensitivity and sub-group analyses 


























(95% CI) 3 
 
Base case NHS and PSS 
perspective, imputed 











 (-2320, 1169) 
Societal perspective, 













QALYs calculated using 
SF-6D, imputed costs 








































ICER denotes incremental cost-effectiveness ratio. Dominated denotes that NPWT is associated with higher costs and lower QALY’s, on average, in comparison to standard dressing. Dominant 
denotes that NPWT is associated with lower costs and higher QALY’s, on average, in comparison to standard dressing.  
 ± Sample size: n=226 (NPWT), n= 234 (standard dressing);  Sample size: n=65 (NPWT), n= 79 (standard dressing); ≠ Sample size: n=35 (NPWT), n=33 (standard dressing). 
1 Assumes a cost-effectiveness threshold of £15,000 per QALY. 2 Assumes a cost-effectiveness threshold of £20,000 per QALY. 3 Assumes a cost-effectiveness threshold of £30,000 per QALY. 
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Appendix I: Completeness of health economic data by trial group, follow-up point and resource 
category 
 
  NPWT 
n (%, N=226) 
Standard 
n (%, N=234) 
Total 
n (%, N=460) 
Health-related quality of life 
 Pre-injury 
baseline EQ-5D 
220 (97%) 231 (99%) 451 (98%) 
Post-injury 
baseline EQ-5D 
210 (93%) 226 (97%) 436 (95%) 
3 month EQ-5D 152 (67%) 175 (75%) 327 (71%) 
6 month EQ-5D 146 (65%) 166 (71%) 312 (68%) 
9 month EQ-5D 144 (64%) 154 (66%) 298 (65%) 
12 month EQ-5D 172 (76%) 192 (82%) 364 (79%) 
QALYs complete 
cases 
94 (42%) 124 (53%) 218 (47%) 
Resource use/Economic costs 
3 months Inpatient care 157 (69%) 174 (74%) 331 (72%) 
Outpatient care 148 (65%) 164 (70%) 312 (68%) 
Community care 148 (65%) 162 (69%) 310 (67%) 
Medications 142 (63%) 159 (68%) 301 (65%) 
Personal social 
services 
144 (64%) 158 (68%) 302 (66%) 
Aids and 
adaptations 
144 (64%) 162 (69%) 306 (67%) 
Total costs 136 (60%) 149 (64%) 285 (62%) 
6 months Inpatient care 145 (64%) 164 (70%) 309 (67%) 
Outpatient care 142 (63%) 157 (67%) 299 (65%) 
Community care 138 (61%) 156 (67%) 294 (64%) 
Medications 136 (60%) 155 (66%) 291 (63%) 
Personal social 
services 
141 (62%) 157 (67%) 298 (65%) 
Aids and 
adaptations 
138 (61%) 156 (67%) 294 (64%) 
Total costs 128 (57%) 149 (64%) 277 (60%) 
9 months Inpatient care 145 (64%) 150 (64%) 295 (64%) 
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Outpatient care 140 (62%) 143 (61%) 283 (62%) 
Community care 138 (61%) 138 (59%) 276 (60%) 
Medications 139 (62%) 143 (61%) 282 (61%) 
Personal social 
services 
141 (62%) 142 (61%) 283 (62%) 
Aids and 
adaptations 
139 (62%) 140 (60%) 279 (61%) 
Total costs 129 (57%) 133 (57%) 262 (57%) 
12 months Inpatient care 168 (74%) 186 (79%) 354 (77%) 
Outpatient care 162 (72%) 180 (77%) 342 (74%) 
Community care 161 (71%) 180 (77%) 341 (74%) 
Medications 159 (70%) 179 (76%) 338 (73%) 
Personal social 
services 
163 (72%) 182 (78%) 345 (75%) 
Aids and 
adaptations 
163 (72%) 180 (77%) 343 (75%) 
Total costs 152 (67%) 170 (73%) 322 (70%) 
Complete cases EQ-5D and 
Economic costs 





Appendix II: Primary initial procedures by trial arm 
 
Primary initial procedure name Number (%) of 
procedures 
NPWT 
Mean (95% CI) 
length of stay 
NPWT 
(days) 
Number (%) of 
procedures 
Standard 
Mean (95% CI) 












Microvascular free tissue transfer of flap of muscle of shoulder 70 (40.0%) 18.5 
(15.9, 21.1) 
60 (25.6%) 20  
(16.1, 24.0) 
0.204 0.512 
Primary open reduction of fracture of bone and external fixation however 
further qualified (HFQ) of knee 
53 (23.5%) 22.7 
(18.3, 27.2) 
60 (25.6%) 18.3 
(14.9, 21.8) 
0.585 0.12 
Primary open reduction of fracture of long bone and fixation using rigid nail 
not elsewhere classified (NEC) of knee 
28 (12.4%) 17.0 
(9.7, 24.3) 
33 (14.1%) 15.2 
(11.4, 18.9) 
0.588 0.654 
Primary open reduction of fracture of long bone and extramedullary fixation 
using plate NEC of knee 
17 (7.5%) 15.2 
(10.7, 19.8) 
17 (7.3%) 15.2 
(8.4, 22.0) 
0.916 0.988 
Microvascular free tissue transfer of flap of muscle of hip 18 (8.0%) 16.9 
(10.7, 23.1) 
14 (6.0%) 28.2 
(13.4, 43.0) 
0.404 0.148 
Primary open reduction of fracture of long bone and fixation using rigid nail 
NEC of hip 
5 (2.2%) 7.4 
(1.2, 13.7) 
9 (3.8%) 14.1 
(7.4, 20.8) 
0.308 0.094 
Primary open reduction of fracture of bone and external fixation HFQ of hip 9 (4.0%) 18.2 
(12.9, 23.6) 
4 (1.7%) 23.8 
(0, 58.5) 
0.141 0.652 
Primary open reduction of fracture of long bone and extramedullary fixation 
using plate NEC of hip 
0 (0%) - 8 (3.4%) 31.5 
(12.2, 50.8) 
0.005 - 
Primary open reduction of fracture dislocation of joint and internal fixation 
NEC of foot 
4 (1.8%) 7.5 
(4.2, 10.8) 
2 (0.9%) 12.5 
(0, 133.2) 
0.387 0.691 
Amputation of leg below knee 4 (1.8%) 33.0 
(5.4, 60.7) 
2 (0.9%) 21.0 
(0, 148.1) 
0.387 0.441 
Primary open reduction of fracture of bone and external fixation HFQ of foot 3 (1.3%) 19.0 
(5.9, 32.1) 
2 (0.9%) 15.5 
(0, 47.3) 
0.625 0.442 
Primary open reduction of fragment of bone and fixation using wire system 
of foot 
3 (1.3%) 5.7 
(0, 15.1) 
2 (0.9%) 20.5 
(0, 115.8) 
0.625 0.279 
Unspecified split autograft of skin 3 (1.3%) 17.0 
(6.2, 27.8) 





Application of external ring fixation to bone NEC of knee 0 (0%) - 3 (1.3%) 30.0 
(10.3, 49.7) 
0.088 - 
Revision of microvascular vessel anastomosis of blood vessel of lower limb 0 (0%) - 3 (1.3%) 33.0 
(0, 83.2) 
0.088 - 
Primary open reduction of fragment of bone and fixation using screw of knee 0 (0%) - 2 (0.9%) 7.0 
(0, 57.8) 
0.164 - 
Amputation of leg above knee 0 (0%) - 2 (0.9%) 40.5 
(0, 428.0) 
0.164 - 
Primary open reduction of fracture of ankle and extramedullary fixation NEC 1 (0.4%) 0 
(-) 
1 (0.4%) 9.0 
(-) 
0.98 - 
Amputation of leg through knee 0 (0%) - 2 (0.9%) 37.0 
(0, 164.1) 
0.164 - 
Primary open reduction of fragment of bone and fixation using wire system 
of knee 
1 (0.4%) 14.0 
(-) 
1 (0.4%) 18.0 
(-) 
0.98 - 
Application of skeletal traction to bone NEC of hip 0 (0%) - 1 (0.4%) 62.0 
(-) 
0.325 - 
Debridement of soft tissue NEC of knee 1 (0.4%) 15.0 
(-) 
0 (0%) - 0.308 - 
Application of external fixation to bone NEC of knee 0 (0%) - 1 (0.4%) 1.0 
(-) 
0.325 - 
Unspecified local flap of skin and muscle 1 (0.4%) 12.0 
(-) 
0 (0%) - 0.308 - 
Application of external fixation to bone NEC of foot 0 (0%)  - 1 (0.4%) 4.0 
(-) 
0.325 - 
Debridement of soft tissue NEC of foot 1 (0.4%)  1.0 
(-) 
0 (0%) - 0.308 - 
Other specified transplantation of muscle of hip 1 (0.4%) 50.0 
(-) 
0 (0%) - 0.308 - 
Primary open reduction of fragment of bone and fixation using screw of foot 1 (0.4%) 7.0 
(-) 
0 (0%) - 0.308 - 





Remanipulation of fracture of bone and external fixation HFQ of knee 0 (0%) - 1 (0.4%) 25.0 
(-) 
0.325 - 
Remanipulation of fragment of bone and fixation using screw of knee 0 (0%) - 1 (0.4%) 2.0 
(-) 
0.325 - 
Primary open reduction of fracture of long bone and extramedullary fixation 
using plate NEC of foot 
1 (0.4%) 8.0 
(-) 
0 (0%) - 0.308 - 
Primary simple repair of tendon of foot 1 (0.4%) 41.0 
(-) 
0 (0%) - 0.308 - 
Total 226 (100.0%) 18.5 
(16.7, 20.3) 




















































 3 months 6 months 9 months 12 months 
Inpatient resource 
use 
n = 157 n = 174  n = 145 n = 164  n = 145 n = 150  n = 168  n = 186  
Readmissions 



































resource use  
























































































































































































resource use  
n = 148 n = 162  n = 138  n = 156  n = 138  n = 138  n = 161  n = 180  
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n = 144  n = 158  n = 141  n = 157  n = 141  n = 142  n = 163  n = 182  






















































Social worker 0.13 
(0.00, 
0.31) 


















































































































































































































































































n = 142  n = 159  n = 136  n = 155  n = 139  n = 143  n = 159  n = 179  
Prescription 
medication 
76 (54%) 85 (53%) 0.991 49 (36%) 74 (48%) 0.044 41 (29%) 47 (33%) 0.541 44 (28%) 67 (37%) 0.057 
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